In the latest trading session, 0.96 million Coherus Biosciences Inc (NASDAQ:CHRS) shares changed hands as the company’s beta touched 0.81. With the company’s most recent per share price at $1.57 changing hands around $0.1 or 6.46% at last look, the market valuation stands at $180.31M. CHRS’s current price is a discount, trading about -89.17% off its 52-week high of $2.97. The share price had its 52-week low at $0.66, which suggests the last value was 57.96% up since then. When we look at Coherus Biosciences Inc’s average trading volume, we note the 10-day average is 1.91 million shares, with the 3-month average coming to 5.02 million.
Analysts gave the Coherus Biosciences Inc (CHRS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CHRS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Coherus Biosciences Inc’s EPS for the current quarter is expected to be -0.13.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Instantly CHRS is in green as seen in intraday trades today. With action -3.40%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 13.41%, with the 5-day performance at -3.40% in the red. However, in the 30-day time frame, Coherus Biosciences Inc (NASDAQ:CHRS) is -5.15% down. Looking at the short shares, we see there were 30.72 million shares sold at short interest cover period of 3.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 73.83% from its recent market value. According to analyst projections, CHRS’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -282.17% plunge from its current level, while the stock would need to soar -282.17% for it to hit the projected low.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Data shows that the Coherus Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -5.15% over the past 6 months, a 64.65% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach -0.65% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 43.88M. 1 analysts are of the opinion that Coherus Biosciences Inc’s revenue for the current quarter will be 60M. The company’s revenue for the corresponding quarters a year ago was 91.52M and 77.06M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -52.06%. The estimates for the next quarter sales put growth at -22.14%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 4.73%. The 2025 estimates are for Coherus Biosciences Inc earnings to increase by 113.96%.
CHRS Dividends
Coherus Biosciences Inc is expected to release its next quarterly earnings report in February.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.38% of Coherus Biosciences Inc shares while 70.34% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 71.33%. There are 70.34% institutions holding the Coherus Biosciences Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 10.4236% of the shares, roughly 11.75 million CHRS shares worth $20.33 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.4035% or 10.6 million shares worth $18.34 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 3.43 shares estimated at $5.32 million under it, the former controlled 2.98% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.47% of the shares, roughly 2.85 shares worth around $4.41 million.
